CVS Health (CVS)
Health Care · Managed Health Care & Pharmacy Services · NYSE
A leading health solutions company integrating retail pharmacy, pharmacy benefit management, and insurance services to manage health costs and improve access to care.
What CVS Health does
CVS Health is a diversified health services company that provides pharmacy, health insurance, and primary care services. The company operates through a large retail pharmacy network, a pharmacy benefit management (PBM) business, and a national health insurance provider. It also provides specialized health services including primary care, home health, and specialty pharmacy solutions.
Themes: pharmacy retail, pharmacy benefit management (PBM), managed care / health insurance, primary care delivery, specialty pharmacy
Fundamentals
- Price$87.80 as of 2026-10-08 close
- Market cap$112.3B as of 2026-07-29 (share count; price 2026-10-08)
- 1-year return+14.1% 2025-10-08 close $76.93 → 2026-10-08 close $87.80
- P/E23.28 as of 2026-10-08
- Net margin+0.4% FY2025, SEC XBRL
- ROE+2.4% FY2025, SEC XBRL
- Debt / equity0.77 as of 2026-09-03
- Revenue growth (YoY)+7.4% as of 2026-09-03
- Revenue CAGR (3y)+7.6% SEC XBRL
- Beta0.29 as of 2026-09-03
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +3.0%; at least 19 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How CVS compares in its sector
- price-to-earnings ratiomiddle range 185 covered Health Care peers, as of 2026-10-08
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldtop 25% 72 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)top 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
CVS is not currently in any published Top 10 list. Its scores are below.
Top 10 score
47.0 #902 of 1,379 scored · #108 of 151 in Health Care
Valuation 78th (price to book 1.4, price to earnings 23.3) and capital return 65th (consecutive years of dividend increases 19 years, net share count bought back over the year -0.7); weakest is profitability (20th, operating margin 1.2%, return on equity 2.4%).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Dividend coverage (FY2025)
Exceeded at least one reported measure. In FY2025, CVS's dividend exceeded at least one reported measure of what it earned or generated (earnings payout 192%, free-cash-flow payout 44%). A payout above 100% in one year is not necessarily unsustainable, but it is not fully covered by that measure.
- Earnings payout192% dividends / net income
- Free-cash-flow payout44% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How CVS Health looks technically
CVS Health (CVS) is trading 0.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 392 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 34, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive). It made a new 20-day low about 11 trading days ago. It is 20.7% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 0.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +0.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $93.28 | $93.28 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $87.56 | $87.56 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 84.23. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a five-part sequence in leg 4. | possible three-wave downward correction, complete (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 392 trading days ago — a "golden cross", a bullish long-term signal | 392 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 0.3% above | +0.3% |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 34, with sellers in control | 34.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30) | 43.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($84.23 to $90.02) — its "stochastic" reading is 62 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 61.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $110.68 | $110.68 |
|---|---|---|
| From the 52-week high | it is 20.7% below its 52-week high (its highest price of the past year) | -20.7% |
| Above the 52-week low | it is 26.3% above its 52-week low (its lowest price of the past year) | +26.3% |
| Below the 52-week high | it is 20.7% below its highest point of the past year | 20.7% |
| Since a 20-day breakout | it made a new 20-day low about 11 trading days ago | 11 sessions |
| Since a 55-day breakout | it made a new 55-day low about 11 trading days ago | 11 sessions |
| All-time high | its highest closing price on record is $113.65 (set on 2015-07-29) | $113.65 |
| Given back of the 52-week move | over the past year its closes ranged ($70.08 to $110.60), and it has given back around half of its rise from last year’s low — 56% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $84.26 to $85.56. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 56.3% |
| From the all-time high | it is 22.7% below its all-time high | -22.8% |
| Nearest price level | it is trading 2.2% below a resistance level at $89.72 — a price it turned at twice since 2026-06-02, most recently on 2026-09-28. Since 2024-10-08 it has 14 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.2% |
| All-time low | its lowest closing price on record is $9.09 (set on 1996-10-28) | $9.09 |
| Above the all-time low | it is 865.5% above its all-time low | +865.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 42nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.15 between its high and its low — about 2.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.15 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $82.40 and $94.78 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $82.40 – $88.59 – $94.78 |
| Typical daily range (% of price) | its price moves about 2.5% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.5% |
| Stretch from the 200-day average | it is trading 0.1 daily ranges above its 200-day average price (0.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.97× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.4% since the prior reading | -0.5% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.1% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.1% |
|---|---|---|
| Gap filled | a 2.1% gap up opened on 2026-07-16 has been "filled" 59 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 59 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 9.6 percentage points (the stock lost 8.6% while the market gained 1.0%) | -9.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 19.8 percentage points (the stock lost 16.0% while the market gained 3.8%) | -19.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 2.4 percentage points (the stock gained 19.8% while the market gained 17.5%) | +2.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 0.8 percentage points (the stock gained 14.1% while the market gained 15.0%) | -0.8% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 10% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 3.9% of the share price. | -10.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is sitting right on the average price paid so far this year, so the typical buyer over that stretch is roughly break-even. That average is $87.56 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +0.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $91.91 — a volume-weighted average of daily closes over 46 sessions, not a true tick-by-tick VWAP. | -4.5% |
Falling wedge, bullish — broke out · entry $85.79 · 56 sessions in
Price levels it has turned at before
CVS last closed at $87.80 on 2026-10-08. Since 2024-10-08 it has turned at 14 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $89.72 | Resistance | 2.2% above the last close | turned there twice · 2026-06-02 to 2026-09-28 |
| $84.46 | Support | 3.8% below the last close | turned there three times · 2025-10-29 to 2026-10-01 |
| $92.68 | Resistance | 5.6% above the last close | turned there twice · 2026-08-11 to 2026-08-21 |
| $81.46 | Support | 7.2% below the last close | turned there five times · 2025-11-12 to 2026-03-03 |
| $79.18 | Support | 9.8% below the last close | turned there four times · 2025-10-03 to 2026-04-09 |
| $98.15 | Resistance | 11.8% above the last close | turned there three times · 2026-05-14 to 2026-09-02 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $84.23.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
Alternate reading: The same swings also read as a five-part sequence in leg 4, which fails on a close above $92.35.
This reading has stood for 21 trading days, since 2026-09-10.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Near 200-day moving-average support · Trading above the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · Printed a doji candle · Trading at this year’s average price paid (anchored VWAP) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.41 mean, 1=Strong Buy…5=Strong Sell) — 25 analysts
- Mean price target$115.76 range $103.00 – $145.00; median $115.00
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CVS
- Consensus EPS estimate$1.64 next reporting period, as of 2026-10-08
- Estimate change, 30 days+$0.01288 (+0.8%) from $1.63, on 2026-09-03, 35-day window
- Readings revised upward25% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Intense competition in pharmacy and health insurance sectors.","Regulatory changes impacting drug pricing and reimbursement models.","Rising costs of health care services and pharmaceutical drugs."]
What changed in the latest 10-Q
AI-assisted comparison of CVS's 10-Q filed 2026-08-05 against the prior one filed 2026-05-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-05) includes a summary of consolidated financial results for the three and six months ended June 30, 2026 and 2025, with year-over-year comparisons for both periods (e.g., products revenue of $66,219 million for Q2 2026 vs $60,607 million for Q2 2025; six-month products revenue of $128,445 million vs $118,276 million).
- Newer filing (2026-08-05) includes commentary for the three months ended June 30, 2026 vs. 2025, with bullet points on revenues, operating expenses, operating income, and income tax provision, including mention of 'the absence of $833 million in legacy litigation charges recorded in the prior year' under operating expenses and operating income.
- Newer filing (2026-08-05) reports an effective income tax rate of 24.7% for the three months ended June 30, 2026.
- Removed:
- Older filing (2026-05-06) includes a summary of consolidated financial results for the three months ended March 31, 2026 and 2025, with year-over-year comparisons (e.g., products revenue of $62,226 million for Q1 2026 vs $57,669 million for Q1 2025).
- Older filing (2026-05-06) includes commentary for the three months ended March 31, 2026 vs. 2025, with bullet points mentioning 'the absence of a $387 million legacy litigation charge and a $247 million pre-tax loss on the wind down and sale of Accountable Care assets' under operating expenses and operating income.
- Older filing (2026-05-06) reports an effective income tax rate of 24.9% for the three months ended March 31, 2026 compared to 31.9% for the three months ended March 31, 2025, with attribution to 'the absence of the impact of the non-deductible legacy litigation charge recorded in the prior year.'
- Older filing (2026-05-06) includes a section titled 'Trends and Uncertainties' at the end (text is truncated in the source, so contents cannot be compared).
- Reworded:
- As of date: Newer filing (2026-08-05) states 'As of June 30, 2026, the Company had approximately 9,000 retail locations... with approximately 87 million plan members'; older filing (2026-05-06) states 'As of March 31, 2026, the Company had approximately 9,000 retail locations... with approximately 88 million plan members.'
- Estimated people served: Newer filing (2026-08-05) states 'The Company also serves an estimated 37 million people'; older filing (2026-05-06) states 'The Company also serves an estimated more than 37 million people.'
- Cordavis subsidiary designation: Newer filing (2026-08-05) refers to 'its Cordavis ® subsidiary'; older filing (2026-05-06) refers to 'its Cordavis TM subsidiary.'
- Reporting period in operating results intro: Newer filing (2026-08-05) explains 'material changes in the Company's operating results for the three and six months ended June 30, 2026 and 2025'; older filing (2026-05-06) explains 'material changes in the Company's operating results for the three months ended March 31, 2026 and 2025.'
- Page number after segment description: Newer filing (2026-08-05) shows '36'; older filing (2026-05-06) shows '32'.
- Notes:
- Both source texts are truncated at the end of the provided excerpts, so later portions of each MD&A (including the 'Trends and Uncertainties' section in the older filing and commentary beyond the income tax provision in the newer filing) are not fully comparable.
- Financial figures in the newer filing cover three and six months ended June 30, while the older filing covers three months ended March 31; the comparison therefore reflects different reporting periods rather than a direct same-period revision.
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 180 days · read to 2026-10-040 buys · 8 sells ($324M) — 2 selling insiders
Most recent open-market transaction: 2026-05-21. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CVS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 15 matched disclosures for CVS from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
7 institutional 13F filers reported holding CVS as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 7
- Reported shares held 237,553,243
- Reported value $24,574,883,131
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 3 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CVS's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CVS had 16,123,980 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
CVS had 1.26% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.14 days to cover at the same settlement.
- Reported short interest (shares) 16,123,980
- Short interest (% of shares outstanding) 1.26%
- Prior settlement (shares) 18,114,651
- Reported change -10.99%
- Days to cover (reported) 3.14
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Walgreens Boots Alliance (WBA)
- Cigna Group (CI)
- UnitedHealth Group (UNH)
- Elevance Health (ELV)
- Humana (HUM)
- Rite Aid (RAD)
- Amazon Pharmacy (AMZN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CVS vs…
CVS Health is found in…
CVS ranks in…
Frequently asked questions
What does CVS Health (CVS) do?
CVS Health is a diversified health services company that provides pharmacy, health insurance, and primary care services. The company operates through a large retail pharmacy network, a pharmacy benefit management (PBM) business, and a national health insurance provider. It also provides specialized health services including primary care, home health, and specialty pharmacy solutions.
What sector is CVS Health (CVS) in?
CVS Health (CVS) is classified in the Health Care sector. Its industry is Managed Health Care & Pharmacy Services. It trades on NYSE.
Does CVS pay a dividend?
Yes — CVS Health (CVS) pays a dividend, with an indicated yield of about 3.02% and at least 19 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-09-03). Informational only — not financial advice.
Who are CVS Health's (CVS) competitors?
Notable peers of CVS Health (CVS) include Walgreens Boots Alliance, Cigna Group, UnitedHealth Group, Elevance Health and Humana. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in CVS?
Yes — we hold 15 matched STOCK Act disclosures for CVS from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is CVS Health (CVS) overbought or oversold right now?
CVS Health (CVS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 43, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CVS come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.